Aziyo Biologics Inc. (AZYO)
Aziyo Biologics Statistics
Share Statistics
Aziyo Biologics has 16.25M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 16.25M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 4.12M |
| Failed to Deliver (FTD) Shares | 4.67K |
| FTD / Avg. Volume | 1.08% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -1.79 and the forward PE ratio is null. Aziyo Biologics's PEG ratio is 0.
| PE Ratio | -1.79 |
| Forward PE | n/a |
| PS Ratio | 1.2 |
| Forward PS | n/a |
| PB Ratio | -11.68 |
| P/FCF Ratio | -2.68 |
| PEG Ratio | 0 |
Enterprise Valuation
Aziyo Biologics has an Enterprise Value (EV) of 76.69M.
| EV / Sales | 1.56 |
| EV / EBITDA | -3.43 |
| EV / EBIT | -3.58 |
| EV / FCF | -3.49 |
Financial Position
The company has a current ratio of 1.19, with a Debt / Equity ratio of -6.32.
| Current Ratio | 1.19 |
| Quick Ratio | 0.95 |
| Debt / Equity | -6.32 |
| Debt / EBITDA | -1.56 |
| Debt / FCF | -1.59 |
| Interest Coverage | -5.02 |
Financial Efficiency
Return on Equity is 653.63% and Return on Invested Capital is -99.2%.
| Return on Equity | 653.63% |
| Return on Assets | -47.79% |
| Return on Invested Capital | -99.2% |
| Revenue Per Employee | $325.74K |
| Profits Per Employee | $-217.86K |
| Employee Count | 151 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 2.98 |
Taxes
| Income Tax | 34K |
| Effective Tax Rate | -0.1% |
Stock Price Statistics
The stock price has increased by 7.19% in the last 52 weeks. The beta is -0.08, so Aziyo Biologics's price volatility has been lower than the market average.
| Beta | -0.08 |
| 52-Week Price Change | 7.19% |
| 50-Day Moving Average | 1.55 |
| 200-Day Moving Average | 2.62 |
| Relative Strength Index (RSI) | 48.31 |
| Average Volume (20 Days) | 432.73K |
Income Statement
In the last 12 months, Aziyo Biologics had revenue of 49.19M and earned -32.9M in profits. Earnings per share was -2.38.
| Revenue | 49.19M |
| Gross Profit | 19.22M |
| Operating Income | -26.54M |
| Net Income | -32.9M |
| EBITDA | -22.38M |
| EBIT | -27.58M |
| Earnings Per Share (EPS) | -2.38 |
Balance Sheet
The company has 16.99M in cash and 34.89M in debt, giving a net cash position of -17.9M.
| Cash & Cash Equivalents | 16.99M |
| Total Debt | 34.89M |
| Net Cash | -17.9M |
| Retained Earnings | -137.99M |
| Total Assets | 54.58M |
| Working Capital | -5.61M |
Cash Flow
In the last 12 months, operating cash flow was -21.43M and capital expenditures -540K, giving a free cash flow of -21.97M.
| Operating Cash Flow | -21.43M |
| Capital Expenditures | -540K |
| Free Cash Flow | -21.97M |
| FCF Per Share | -1.59 |
Margins
Gross margin is 39.08%, with operating and profit margins of -53.96% and -66.88%.
| Gross Margin | 39.08% |
| Operating Margin | -53.96% |
| Pretax Margin | -66.81% |
| Profit Margin | -66.88% |
| EBITDA Margin | -45.5% |
| EBIT Margin | -53.96% |
| FCF Margin | -44.67% |
Dividends & Yields
AZYO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -55.96% |
| FCF Yield | -37.38% |
Analyst Forecast
Currently there are no analyst rating for AZYO.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -5.39 |
| Piotroski F-Score | 3 |